Sarepta Therapeutics, Inc.
SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exonā¦ read more
Healthcare
Biotechnology
28 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$19.13
Price-1.39%
-$0.27
1Y
Price
Market Cap
$2.020b
Mid
Price/Earnings 3y Avg5y Avg
54.7x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+50.9%
EBITDA Margin+45.3%
Net Profit Margin-28.0%
Free Cash Flow Margin+50.9%
EBITDA Margin+45.3%
Net Profit Margin-28.0%
Free Cash Flow MarginRevenue
$2.184b
-0.6%
1y CAGR+22.6%
3y CAGR+25.3%
5y CAGREarnings
$65.057m
+109.1%
1y CAGR-50.1%
3y CAGR-31.6%
5y CAGREPS
-$0.96
+86.5%
1y CAGR-59.3%
3y CAGR-37.5%
5y CAGRBook Value
$1.505b
$3.179b
Assets$1.674b
Liabilities$1.037b
DebtDebt to Assets
32.6%
8.5x
Debt to EBITDAFree Cash Flow
$107.135m
+134.9%
1y CAGR+62.6%
3y CAGR+30.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company